In a recent study, the researchers found that treatment with anti-bone morphogenetic protein 1 (anti-BMP1) antibodies dose-dependently increased lesion volume in mice with endometriosis, reduced IL-17 and IL-1β levels 105. The gene discussed is IL17A; the disease is endometriosis.